Echelon Biosciences, Inc.

Founded in 1997 and based in Utah, US, Echelon Biosciences, Inc. specializes in the development and production of research reagents and assays related to lipid and cell signaling for different illnesses and critical diseases. In August 2024, VION Biosciences LLC, a portfolio company of Iron Path Capital, Echelon Biosciences offers a comprehensive portfolio of products and services that cater to the needs of researchers in the fields of lipid signaling, cell signaling, and related areas of study. The company’s product categories include biochemical reagents, lipids, peptides, antibodies, and proteins for researchers studying biological processes at the molecular level.

Additionally, the firm offers a range of kits and assays designed to facilitate the detection and quantification of specific biomolecules for various applications, from basic research to drug discovery and development. Echelon’s expertise in lipid chemistry and peptide synthesis allows the company to offer custom synthesis services. This includes the production of complex lipids, peptides, and other novel molecules tailored to the specific needs of researchers. The business offers LNP services to accelerate the formulation and development of lipid-based drug delivery systems.

Echelon also offers nanobody production services, providing researchers with access to these small, antibody-like molecule properties for use in various research applications.